|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Pulmatrix Presents Data on iSPERSE for Inhaled Combination Drug Therapies, Including Triple Drug Combinations
12/19/2011 6:05:58 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that its iSPERSE™ inhaled drug platform demonstrated multi-drug delivery capability and superiority over conventional lactose blending for an effective therapeutic dose of the active ingredients in Advair®, salmeterol and fluticasone, as well as an additional anticholinergic bronchodilator. These preclinical data highlight the capability of iSPERSE, a proprietary salt formulation inhaled as a dry powder, to efficiently deliver consistent double- and triple-combination drug doses across a broad range of flow rates, which offers the potential of improved drug efficacy and safety for patients having both normal and lower or impaired lung function. These results were presented in a poster entitled “Pulmonary Delivery of Combination Drug Products via a Novel Dry Powder Delivery Technology” at the 11th US-Japan Symposium on Drug Delivery Systems on December 15-20, 2011, in Lahaina, Hawaii.
|
|
|
|
|
|
|
|
|
|
|